Literature DB >> 1984475

Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay.

R B Lal1, D L Rudolph, M D Lairmore, R F Khabbaz, M Garfield, J E Coligan, T M Folks.   

Abstract

Synthetic peptides corresponding with unique regions of the envelope glycoproteins (gp46) of human T cell lymphotropic viruses (HTLVs) were used in an enzyme immunoassay to determine if HTLV-I and -II infections could be discriminated. Two synthetic HTLV-I sequence-derived peptides, Env-1 (amino acids 191-215) and Env-5 (amino acids 242-257), reacted with 92% and 100% of the serum specimens (n = 52) from HTLV-I-infected persons, respectively. Although a small percentage (8.6%) of serum specimens from persons infected with HTLV-II cross-reacted with Env-1, none of these specimens reacted with Env-5. Peptide Env-2 encoded by the envelope region of HTLV-II (amino acids 187-210) reacted with serum specimens from both HTLV-I (94%)- and HTLV-II (74%)-infected patients, whereas Env-6, another HTLV-II peptide (amino acids 238-254), reacted with less than 6% of the specimens. Therefore, the Env-5 peptide with amino acid sequence SerProAsnValSerValProSerSerSerSerThrProLeuLeuTyr represents an immunodominant domain of HTLV-I that is recognized by serum antibodies from all HTLV-I-infected persons. Moreover, the Env-5-based ELISA allows a categorical distinction between the closely related HTLV-I and -II infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984475     DOI: 10.1093/infdis/163.1.41

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Complete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi Indian.

Authors:  D Pardi; W M Switzer; K G Hadlock; J E Kaplan; R B Lal; T M Folks
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals.

Authors:  R B Lal; W Heneine; D L Rudolph; W B Present; D Hofhienz; T M Hartley; R F Khabbaz; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Characterization of B cell epitopes on the 16K antigen of Mycobacterium tuberculosis.

Authors:  A Verbon; R A Hartskeerl; C Moreno; A H Kolk
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

5.  Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.

Authors:  D Pardi; J E Kaplan; J E Coligan; T M Folks; R B Lal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Isolation and characterization of simian T-cell leukemia virus type II from New World monkeys.

Authors:  Y M Chen; Y J Jang; P J Kanki; Q C Yu; J J Wang; R J Montali; K P Samuel; T S Papas
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Concomitant augmentation of CD4+ CD29+ helper inducer and diminution of CD4+ CD45RA+ suppressor inducer subset in patients infected with human T cell lymphotropic virus types I or II.

Authors:  R B Lal; D L Rudolph; D S Schmid; M D Lairmore
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

8.  Phenotypic expression of integrin membrane receptors on spontaneously proliferating CD8 cells in human T-lymphotropic virus type II (HTLV-II)-infected individuals.

Authors:  R B Lal; D L Rudolph; T Rowe; T M Folks
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

9.  Discrimination between human T-cell lymphotropic virus type I and II (HTLV-I and HTLV-II) infections by using synthetic peptides representing an immunodominant region of the core protein (p19) of HTLV-I and HTLV-II.

Authors:  J Bonis; A Baillou; F Barin; M Verdier; B Janvier; F Denis
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

10.  Serologic confirmation of simian T-lymphotropic virus type I infection by using immunoassays developed for human T-lymphotropic virus antibody detection.

Authors:  D L Rudolph; J Yee; J Mone; S K Foung; J J Lipka; G R Reyes; K Hadlock; L Chan; F Villinger; M D Lairmore
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.